MX2023012351A - Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). - Google Patents
Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).Info
- Publication number
- MX2023012351A MX2023012351A MX2023012351A MX2023012351A MX2023012351A MX 2023012351 A MX2023012351 A MX 2023012351A MX 2023012351 A MX2023012351 A MX 2023012351A MX 2023012351 A MX2023012351 A MX 2023012351A MX 2023012351 A MX2023012351 A MX 2023012351A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- antibodies binding
- bispecific antibodies
- dosage forms
- unit dosage
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 title abstract 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas y formas de dosificación unitaria que comprenden anticuerpos que se unen a B7H4 y CD3. La invención proporciona además un uso de las composiciones farmacéuticas y formas de dosificación unitaria para procedimientos terapéuticos y de diagnóstico, en particular en la terapia contra el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163185762P | 2021-05-07 | 2021-05-07 | |
PCT/EP2022/062518 WO2022234146A1 (en) | 2021-05-07 | 2022-05-09 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023012351A true MX2023012351A (es) | 2023-10-31 |
Family
ID=81974983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023012351A MX2023012351A (es) | 2021-05-07 | 2022-05-09 | Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4334359A1 (es) |
JP (1) | JP2024519212A (es) |
KR (1) | KR20240004949A (es) |
CN (1) | CN117396509A (es) |
AR (1) | AR125815A1 (es) |
AU (1) | AU2022268652A1 (es) |
BR (1) | BR112023021089A2 (es) |
CA (1) | CA3214582A1 (es) |
IL (1) | IL308300A (es) |
MX (1) | MX2023012351A (es) |
WO (1) | WO2022234146A1 (es) |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
KR20040088572A (ko) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
TW200938224A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
RU2744176C2 (ru) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
MX2011009810A (es) | 2009-03-27 | 2011-09-30 | Zymogenetics Inc | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
RU2016105962A (ru) | 2009-12-04 | 2018-11-23 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
CN106279416B (zh) | 2010-03-04 | 2019-08-30 | 宏观基因有限公司 | 与b7-h3反应性的抗体、其免疫学活性片段及其用途 |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
CN103154035B (zh) | 2010-05-27 | 2017-05-10 | 根马布股份公司 | 针对her2的单克隆抗体 |
ES2537207T3 (es) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Métodos para la generación de anticuerpos multiespecíficos y multivalentes |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
SI2838918T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
US9963512B2 (en) | 2012-11-21 | 2018-05-08 | Pharmabcine Inc. | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same |
BR112015022019A2 (pt) | 2013-03-14 | 2017-08-29 | Genentech Inc | Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer |
KR102363220B1 (ko) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
WO2018021301A1 (ja) * | 2016-07-26 | 2018-02-01 | 静岡県 | 抗b7-h4抗体 |
CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
WO2019165077A1 (en) * | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
AU2019375014A1 (en) * | 2018-11-06 | 2021-05-27 | BioNTech SE | Antibody formulation |
EP4013509A1 (en) * | 2019-08-15 | 2022-06-22 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
BR112022015572A2 (pt) * | 2020-03-18 | 2022-09-27 | Genmab As | Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes |
-
2022
- 2022-05-09 WO PCT/EP2022/062518 patent/WO2022234146A1/en active Application Filing
- 2022-05-09 MX MX2023012351A patent/MX2023012351A/es unknown
- 2022-05-09 CN CN202280033116.8A patent/CN117396509A/zh active Pending
- 2022-05-09 IL IL308300A patent/IL308300A/en unknown
- 2022-05-09 EP EP22728462.7A patent/EP4334359A1/en active Pending
- 2022-05-09 BR BR112023021089A patent/BR112023021089A2/pt unknown
- 2022-05-09 JP JP2023568247A patent/JP2024519212A/ja active Pending
- 2022-05-09 AR ARP220101222A patent/AR125815A1/es unknown
- 2022-05-09 CA CA3214582A patent/CA3214582A1/en active Pending
- 2022-05-09 AU AU2022268652A patent/AU2022268652A1/en active Pending
- 2022-05-09 KR KR1020237041813A patent/KR20240004949A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
KR20240004949A (ko) | 2024-01-11 |
AU2022268652A1 (en) | 2023-10-05 |
JP2024519212A (ja) | 2024-05-09 |
BR112023021089A2 (pt) | 2023-12-12 |
AU2022268652A9 (en) | 2024-02-22 |
CN117396509A (zh) | 2024-01-12 |
WO2022234146A1 (en) | 2022-11-10 |
AR125815A1 (es) | 2023-08-16 |
IL308300A (en) | 2024-01-01 |
CA3214582A1 (en) | 2022-11-10 |
EP4334359A1 (en) | 2024-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220521A (es) | Anticuerpos | |
PH12020551447A1 (en) | Antibodies | |
PH12020551908A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
MY191423A (en) | Binding molecules specific for cd73 and uses thereof | |
MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
MX357100B (es) | Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4. | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
MX2021013943A (es) | Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. | |
MX2023012351A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). | |
MX2024002781A (es) | Anticuerpos capaces de unirse a cumulo de diferenciacion 27 (cd27), variantes de los mismos y usos de los mismos. | |
ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
MX2023013165A (es) | Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico. | |
MX2023003749A (es) | Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3). | |
MX2023014899A (es) | Nuevos conjugados que comprenden fosfoantígenos y su uso en terapia. | |
MX2023007178A (es) | Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo. | |
MX2022005400A (es) | Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos. | |
EA202092151A1 (ru) | Антитела | |
MX2022005032A (es) | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). |